Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8349811 | Pharmacological Reports | 2017 | 20 Pages |
Abstract
We conclude that one of the possible regulatory mechanisms of TNF in pain involves upregulation of the nociceptor TRPV1, and that peripheral treatment with a selective anti-soluble TNF biologic can prevent hyperalgesia caused by inflammation in the orofacial region. Therefore, these new findings suggest that XPro1595 may serve as a novel treatment for orofacial pain disorders.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biochemistry
Authors
Krzysztof Lis, Tomasz Grygorowicz, Agnieszka Cudna, David E. Szymkowski, Ewa BaÅkowiec-Iskra,